keyword
MENU ▼
Read by QxMD icon Read
search

Who ovarian cancer

keyword
https://www.readbyqxmd.com/read/28430350/1st-evidence-based-italian-consensus-conference-on-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-carcinosis-from-ovarian-cancer
#1
Davide Cavaliere, Roberto Cirocchi, Federico Coccolini, Anna Fagotti, Massimiliano Fambrini, Orietta Federici, Domenica Lorusso, Marco Vaira, Marco Ceresoli, Paolo Delrio, Alfredo Garofalo, Sandro Pignata, Paolo Scollo, Vito Trojano, Andrea Amadori, Luca Ansaloni, Giuseppe Cariti, Franco De Cian, Pierandrea De Iaco, Michele De Simone, Marcello Deraco, Annibale Donini, Giammaria Fiorentini, Luigi Frigerio, Stefano Greggi, Antonio Macrì, Enrico Maria Pasqual, Franco Roviello, Paolo Sammartino, Cinzia Sassaroli, Giovanni Scambia, Carlo Staudacher, Patrizia Vici, Enrico Vizza, Mario Valle
Ovarian cancer (OC) remains relatively rare, although it is among the top 4 causes of cancer death for women younger than 50. The aggressive nature of the disease and its often late diagnosis with peritoneal involvement have an impact on prognosis. The current scientific literature presents ambiguous or uncertain indications for management of peritoneal carcinosis (PC) from OC, both owing to the lack of sufficient scientific data and their heterogeneity or lack of consistency. Therefore, the Italian Society of Surgical Oncology (SICO), the Italian Society of Obstetrics and Gynaecology, the Italian Association of Hospital Obstetricians and Gynaecologists, and the Italian Association of Medical Oncology conducted a multidisciplinary consensus conference (CC) on management of advanced OC presenting with PC during the SICO annual meeting in Naples, Italy, on September 10-11, 2015...
April 20, 2017: Tumori
https://www.readbyqxmd.com/read/28428125/ovarian-metastasis-of-a-malignant-melanoma-a-case-report
#2
A Mendel, J J Terzibachian, F Aubin, L Malicenco, R Ramanah, D Riethmuller
Malignant melanoma represents 3% of cancers at the woman. The metastatic gynecological localization are rare and ovary is an exceptional site. Prognosis of metastatic ovary malignant melanoma is pejorative (5% 5 years survival). We report a case observed in a 65-year-old patient, who developed 2 melanomas of the left leg and presented a right ovarian tumor during a supervision tomodensitometric 7 years after diagnostic initial. The immunohistochemical assays after annexectomy confirmed the diagnostic of ovarian metastasis...
April 17, 2017: J Gynecol Obstet Hum Reprod
https://www.readbyqxmd.com/read/28421497/chapter-13-human-ovarian-tissue-vitrification
#3
Sherman Silber
Ovarian freezing and transplantation has garnered increasing interest as a potential way of preserving fertility in cancer patients as well as for women who just wish to delay childbearing. This chapter spells out our techniques of ovarian cortex vitrification and results for frozen compared to fresh ovarian cortex transplantation (in one single series from one center for the sake of consistency), as well as potentially provides insight into the mechanism behind ovarian follicle recruitment. This represents an effort to simplify and popularize an approach that has yielded favorable results (all cases recovered ovulation and 75% had successful spontaneous pregnancy) in one single, disciplined study...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28418343/the-use-of-human-epididymis-4-and-cancer-antigen-125-tumor-markers-in-the-benign-or-malignant-differential-diagnosis-of-pelvic-or-adnexal-masses
#4
Zehra Nihal Dolgun, Canan Kabaca, Ateş Karateke, Cem İyibozkurt, Cihan İnan, Ahmet Salih Altıntaş, Cihan Karadağ
BACKGROUND: Ovarian cancer is one of the highest mortality cancers in gynaecology. Discrimination of benign masses from malignant ones may sometimes become a challenge for the clinician since there is not a reliable tumour marker, thus some unnecessary, highly morbid operations can be performed. AIMS: To explore the efficacy of human epididymis 4 (HE 4) and cancer antigen 125 (CA 125) markers in differentiating malignant and benign pelvic masses of ovarian origin and to identify the cut-off points for those markers...
April 5, 2017: Balkan Medical Journal
https://www.readbyqxmd.com/read/28418211/cutting-costs-and-standardizing-care-once-per-cycle-complete-blood-count-monitoring-may-be-safe-for-patients-undergoing-platinum-based-chemotherapy
#5
Christine Garcia, Lauren Montemorano, Erin Saks, Linda R Duska, Leigh A Cantrell
AIM: The aim of this study was to evaluate whether frequency of complete blood count (CBC) testing during chemotherapy for gynecologic cancer impacts hospital admissions or rates of neutropenic fever. METHODS: A retrospective cohort study was performed at a single academic institution. Patients undergoing platinum-based chemotherapy for endometrial or ovarian cancer from January 2010 to December 2014 were identified from a clinical database. Patients receiving dose-dense chemotherapy or on a clinical trial were excluded...
April 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28416763/hormone-receptor-expression-profiles-differ-between-primary-and-recurrent-high-grade-serous-ovarian-cancers
#6
Zheng Feng, Hao Wen, Xingzhu Ju, Rui Bi, Xiaojun Chen, Wentao Yang, Xiaohua Wu
Hormone receptor status assessment is necessary for selecting cancer patients who might potentially benefit from endocrine therapy. To determine whether hormone receptor status changes during tumor progression, we retrospectively examined 107 high-grade serous ovarian cancer (HGSC) patients with paired primary and recurrent tumor specimens. Hormone receptor expression discordance rates between primary and recurrent tumors were as follows: estrogen receptor (ER) 34.9%, progesterone receptor (PR) 12.4%, androgen receptor (AR) 41...
March 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28413668/palb2-mutation-in-a-woman-with-bilateral-breast-cancer-a-case-report
#7
Hiroshi Nakagomi, Yosuke Hirotsu, Kenichiro Okimoto, Ikuko Sakamoto, Kenji Amemiya, Satoko Nakagomi, Takeo Kubota, Hitoshi Mochizuki, Masao Omata
Partner and localizer of breast cancer 2 (PALB2) was identified as a moderate-risk gene of breast and pancreas cancer. The present authors previously reported that no PALB2 germline mutations with a deleterious frameshift or stop codons were identified in 155 Japanese patients with breast and/or ovarian cancer who were estimated to be at risk of hereditary cancer, according to the National Comprehensive Cancer Network (NCCN) criteria. In the present study, one patient with a deleterious mutation of PALB2 (c...
April 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28407996/a-multigene-test-could-cost-effectively-help-extend-life-expectancy-for-women-at-risk-of-hereditary-breast-cancer
#8
Yonghong Li, Andre R Arellano, Lance A Bare, Richard A Bender, Charles M Strom, James J Devlin
BACKGROUND: The National Comprehensive Cancer Network recommends that women who carry gene variants that confer substantial risk for breast cancer consider risk-reduction strategies, that is, enhanced surveillance (breast magnetic resonance imaging and mammography) or prophylactic surgery. Pathogenic variants can be detected in women with a family history of breast or ovarian cancer syndromes by multigene panel testing. OBJECTIVES: To investigate whether using a seven-gene test to identify women who should consider risk-reduction strategies could cost-effectively increase life expectancy...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28406427/ten-important-considerations-for-ovarian-cancer-screening
#9
REVIEW
Edward J Pavlik
The unique intricacies of ovarian cancer screening and perspectives of different screening methods are presented as ten considerations that are examined. Included in these considerations are: (1) Deciding on the number of individuals to be screened; (2) Anticipating screening group reductions due to death; (3) Deciding on the duration and frequency of screening; (4) Deciding on an appropriate follow-up period after screening; (5) Deciding on time to surgery when malignancy is suspected; (6) Deciding on how screen-detected ovarian cancers are treated and by whom; (7) Deciding on how to treat the data of enrolled participants; (8) Deciding on the most appropriate way to assign disease-specific death; (9) Deciding how to avoid biases caused by enrollments that attract participants with late-stage disease who are either symptomatic or disposed by factors that are genetic, environmental or social; and (10) Deciding whether the screening tool or a screening process is being tested...
April 13, 2017: Diagnostics
https://www.readbyqxmd.com/read/28405120/fractionated-palliative-pelvic-radiotherapy-as-an-effective-modality-in-the-management-of-recurrent-refractory-epithelial-ovarian-cancers-an-institutional-experience
#10
Anshuma Bansal, Bhavana Rai, Shikhar Kumar, Vanita Suri, Sushmita Ghoshal
BACKGROUND: The advent of effective chemotherapeutic agents for ovarian carcinoma has made radical abdomino-pelvic radiation redundant. Nevertheless, palliative pelvic radiotherapy still has a role in palliating local symptoms. However, its effect on progression-free survival (PFS) may be debated. AIMS: To study the outcome of fractionated palliative pelvic radiotherapy in relapsed ovarian cancers in terms of symptom control and PFS. METHODS: Twenty-three patients of ovarian cancers, heavily pretreated with chemotherapy and with recurrent or residual pelvic masses, were planned for palliative pelvic radiotherapy to the dose of 46-50 Gy in 23-25 fractions in 4...
April 2017: Journal of Obstetrics and Gynaecology of India
https://www.readbyqxmd.com/read/28404569/analysis-suggests-wider-use-for-parp-inhibitors
#11
(no author information available yet)
Researchers have developed a new tool, HRDetect, to pinpoint tumors that display BRCA deficiency but don't harbor BRCA1/2 mutations. Evaluating their method in breast, ovarian, and pancreatic cancers, they identified patients whose tumors were potentially vulnerable to PARP inhibition but who didn't carry these mutations.
April 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28400146/comparison-of-four-brief-depression-screening-instruments-in-ovarian-cancer-patients-diagnostic-accuracy-using-traditional-versus-alternative-cutpoints
#12
Eileen H Shinn, Alan Valentine, George Baum, Cindy Carmack, Kelly Kilgore, Diane Bodurka, Karen Basen-Engquist
OBJECTIVES: We compared the diagnostic accuracy of 4 depression screening scales, using traditional and alternative scoring methods, to the gold standard Structured Clinical Interview-DSM IV major depressive episode (MDE) in ovarian cancer patients on active treatment. METHODS: At the beginning of a new chemotherapy regimen, ovarian cancer patients completed the following surveys on the same day: the Center for Epidemiological Studies Depression Scale (CES-D), the Beck Depression Inventory Fast-Screen for Primary Care (BDI-FastScreen), the Patient Health Questionnaire-9 (PHQ-9), and a 1-item screener ("Are you depressed?")...
April 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28399596/antral-follicles-count-and-anti-m%C3%A3-llerian-hormone-levels-after-gonadotoxic-chemotherapy-in-patients-with-breast-cancer-cohort-study
#13
Ângela Marcon D'Avila, Edison Capp, Helena von Eye Corleta
Aim To assess ovarian reserve (OVR) by means of follicle-stimulating hormone (FSH), anti-Müllerian hormone (AMH), and antral follicle count (AFC) measurement in eumenorrheic women with breast cancer, exposed to gonadotoxic chemotherapy. Method Fifty-two women (35.3 ± 3.8 years old) with breast cancer and undergoing cyclophosphamide-containing chemotherapy were enrolled. The assessment was performed before chemotherapy (T1) and after 2 (T2) and 6 months (T3). Results Six months after chemotherapy, the prevalence of regular cycles was 60%...
April 2017: Revista Brasileira de Ginecologia e Obstetrícia
https://www.readbyqxmd.com/read/28398847/traceback-a-proposed-framework-to-increase-identification-and-genetic-counseling-of-brca1-and-brca2-mutation-carriers-through-family-based-outreach
#14
Goli Samimi, Marcus Q Bernardini, Lawrence C Brody, Charlisse F Caga-Anan, Ian G Campbell, Georgia Chenevix-Trench, Fergus J Couch, Michael Dean, Joanne A de Hullu, Susan M Domchek, Ronny Drapkin, Heather Spencer Feigelson, Michael Friedlander, Mia M Gaudet, Marline G Harmsen, Karen Hurley, Paul A James, Janice S Kwon, Felicitas Lacbawan, Stephanie Lheureux, Phuong L Mai, Leah E Mechanic, Lori M Minasian, Evan R Myers, Mark E Robson, Susan J Ramus, Lisa F Rezende, Patricia A Shaw, Thomas P Slavin, Elizabeth M Swisher, Masataka Takenaka, David D Bowtell, Mark E Sherman
In May 2016, the Division of Cancer Prevention and the Division of Cancer Control and Population Sciences, National Cancer Institute, convened a workshop to discuss a conceptual framework for identifying and genetically testing previously diagnosed but unreferred patients with ovarian cancer and other unrecognized BRCA1 or BRCA2 mutation carriers to improve the detection of families at risk for breast or ovarian cancer. The concept, designated Traceback, was prompted by the recognition that although BRCA1 and BRCA2 mutations are frequent in women with ovarian cancer, many such women have not been tested, especially if their diagnosis predated changes in testing guidelines...
April 11, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28398023/clinical-profile-of-women-with-vva-who-are-not-candidates-for-local-vaginal-oestrogen-therapy
#15
Rossella E Nappi, Filippo Murina, Giuseppina Perrone, Paola Villa, Nicoletta Biglia
Vulvar and vaginal atrophy (VVA) is a chronic medical condition in postmenopausal women, which is predominantly due to a permanent cessation of ovarian oestrogen production. Current available treatment options for VVA are over-the-counter (OTC) symptomatic relief products or local oestrogen therapy (LET) aiming to treat this underlying atrophic condition. Recent surveys indicated that these products decrease sexual spontaneity, are messy and indiscrete. Ospemifene is an oral daily drug, which has proven to treat vaginal dryness and dyspareunia effectively...
April 10, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28395560/fertility-preservation-in-women-with-cns-tumors
#16
Alicia Tosoni, Damiano Balestrini, Alba A Brandes
Fertility impairment due to treatments is a major concern for adolescents and young adult patients who survived cancer. Areas covered: Chemotherapy may determine a detrimental effect on ovary function, leading to infertility, and premature ovarian failure. Embryo and oocyte cryopreservation is a standard strategy for fertility preservation; other strategies, such as gonadal tissue cryopreservation and the use of gonadotropin - releasing hormone agonist, are still considered experimental. There are few data available regarding the effect of pregnancy on glioma, which indicates tumor progression during pregnancy in 33-45% of patients...
May 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28390820/mortality-reduction-and-cost-effectiveness-of-performing-hysterectomy-at-the-time-of-risk-reducing-salpingo-oophorectomy-for-prophylaxis-against-serous-serous-like-uterine-cancers-in-brca1-mutation-carriers
#17
Laura J Havrilesky, Haley A Moss, Junzo Chino, Evan R Myers, Noah D Kauff
OBJECTIVE: To estimate the survival benefit and cost-effectiveness of performing hysterectomy during risk-reducing salpingo-oophorectomy (RRSO) for BRCA1 mutation carriers. METHODS: Based on a recent prospective cohort study indicating an elevated incidence of serous/serous-like uterine cancers among BRCA1 mutation carriers, we constructed a modified Markov decision model from a payer perspective to inform decisions about performance of hysterectomy during RRSO at age 40...
April 5, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28389144/clear-cell-carcinomas-of-the-ovary-have-poorer-outcomes-compared-with-serous-carcinomas-results-from-a-single-center-taiwanese-study
#18
Fei-Chun Ku, Ren-Chin Wu, Lan-Yan Yang, Yun-Hsin Tang, Wei-Yang Chang, Jung-Erh Yang, Chun-Chieh Wang, Shih-Ming Jung, Cheng-Tao Lin, Ting-Chang Chang, Angel Chao, Chyong-Huey Lai
BACKGROUND/PURPOSE: To compare the clinical outcomes of Taiwanese patients with ovarian clear cell carcinomas (CCCs) and serous carcinomas (SCs). METHODS: We retrieved the clinical records of women with epithelial ovarian cancer (Stage I-IV) who received primary surgeries between 2000 and 2013. Cancer-specific survival (CSS), progression-free survival, and survival after recurrence (SAR) of CCC and SC patients were retrospectively compared. Multivariate analysis was used to identify the independent predictors of survival...
April 4, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28388839/critical-depurinating-dna-adducts-estrogen-adducts-in-the-etiology-and-prevention-of-cancer-and-dopamine-adducts-in-the-etiology-and-prevention-of-parkinson-s-disease
#19
REVIEW
Ercole L Cavalieri, Eleanor G Rogan, Muhammad Zahid
Endogenous estrogens become carcinogens when dangerous metabolites, the catechol estrogen quinones, are formed. In particular, the catechol estrogen-3,4-quinones can react with DNA to produce an excess of specific depurinating estrogen-DNA adducts. Loss of these adducts leaves apurinic sites in the DNA, generating subsequent cancer-initiating mutations. Unbalanced estrogen metabolism yields excessive catechol estrogen-3,4-quinones, increasing formation of depurinating estrogen-DNA adducts and the risk of initiating cancer...
April 7, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28383367/laparoscopy-compared-with-laparotomy-for-debulking-ovarian-cancer-after-neoadjuvant-chemotherapy
#20
Alexander Melamed, Roni Nitecki, David M Boruta, Marcela G Del Carmen, Rachel M Clark, Whitfield B Growdon, Annekathryn Goodman, John O Schorge, J Alejandro Rauh-Hain
OBJECTIVE: To compare 3-year survival, length of hospitalization, perioperative mortality, risk of readmission, and residual disease associated with laparoscopic and laparotomic interval debulking surgery among women with epithelial ovarian cancer. METHODS: We used the National Cancer Database to identify a cohort of patients diagnosed with stage IIIC and IV epithelial ovarian cancer between 2010 and 2012 who underwent neoadjuvant chemotherapy and interval debulking surgery...
May 2017: Obstetrics and Gynecology
keyword
keyword
100582
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"